CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Modification of the flt3 mutational status between diagnosis and relapsed/refractory aml: a meta-analysis.

Author: 
Silva, LT., Campos, CCAP., Salvino, M.A.
Subject Area: 
Physical Sciences and Engineering
Abstract: 

Acute myeloid leukemia (AML) is a hematologic cancer with a high mortality and the FLT3 mutations are recognized as one of the most important alteration associated with AML and are related with a poor prognosis. Some studies have revealed that at diagnosis, patients with AML with FLT3 can maintain the alteration in the relapse or refractory disease, although this is not always the rule. This report is a meta-analysis review about the genetic change of FLT3 mutation in the relapsed/refractory AML scenario and if this what differs from findings at diagnosis in the same patients. A search in June/2020 was performed in PUBMED to identify studies with the terms FLT3 (title/abstract) AND “Acute Myeloid Leukemia” without a restrict date. Six articles described mutation status in both FLT3 alterations. The total of 272 patients with relapse and refractory AML were analyzed, 74 (27%) were positive for FLT3-ITD at diagnosis and 15 (5%) for FLT3-TKD. The change in mutation status occurred in 17% of patients. Mutation status change from negative to FLT3-ITD occurred in 7% of patients, FLT3-ITD to negative in 5%. From those that were FLT3-ITD positive 60 remained positive in the relapse. Our data demonstrated that 41% of patients were positive for FLT3 mutation in some point of the disease. Since one in six patients had their mutational status change in the study, reassessment should be mandatory in any case of relapse and refractoriness. If this is related with worst prognostic more studies are needed to elucidate.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran